Slawomir Wojtowicz‐Praga

Author

Georgetown University

Also Known As

S Wojtowicz-Praga, S. Wojtowicz-Praga, Slawomir M. Wojtowicz-Praga, Slawomir Wojtowicz-Praga, Slawomir Wojtowicz‐Praga

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Georgetown University St. Louis Children's Hospital Children's of Alabama Children's Healthcare of Atlanta Theradex Oncology (United States)

About

Slawomir Wojtowicz‐Praga is an author at Georgetown University specializing in radiation oncology, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	606
2	Immunology	3	3	436
3	Cell Biology	2	2	410
4	Pathology	2	2	141
5	Health Sciences	1	1	29

Slawomir Wojtowicz‐Praga

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. Slawomir Wojtowicz‐Praga, Jeff Torri, Michael D. Johnson, Journal of Clinical Oncology	1998	253
Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. Slawomir Wojtowicz‐Praga PubMed ImmunologyImmune RegulationImmunoeditingTgf BetaImmunologic Mechanism	1997	222
Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease Eugene P. Orringer, James F. Casella, Kenneth I. Ataga, JAMA	2001	194
Reversal of Tumor-Induced Immunosuppression: A New Approach to Cancer Therapy Slawomir Wojtowicz‐Praga Journal of Immunotherapy Tgfβ ProductionImmunologyImmune RegulationImmunoeditingImmunologic Mechanism	1997	188
Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5) Andres Forero‐Torres, Jatin J. Shah, Tina E. Wood, Cancer Biotherapy and Radiopharmaceuticals	2010	141
Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer Slawomir Wojtowicz‐Praga, Jennifer A. Low, John L. Marshall, Investigational New Drugs Advanced CancerMedicineMetronomic TherapyPathologyCancer Treatment	1996	128
Modulation of B16 Melanoma Growth and Metastasis by Anti-Transforming Growth Factor ?? Antibody and Interleukin-2 Slawomir Wojtowicz‐Praga, Udit M. Verma, Lalage M. Wakefield, Journal of Immunotherapy	1996	60
Safety of Purified Poloxamer 188 in Sickle Cell Disease: Phase I Study of a Non‐ionic Surfactant in the Management of Acute Chest Syndrome Samir K. Ballas, Beatrice Files, Lori Luchtman‐Jones, Hemoglobin	2004	50
Secretory Phospholipase A<sub>2</sub>Levels in Patients with Sickle Cell Disease and Acute Chest Syndrome Samir K. Ballas, Beatrice Files, Lori Luchtman‐Jones, Hemoglobin	2006	33
Phase I Study of Prolonged Infusion Bryostatin-1 in Patients John L. Marshall, Neelesh S. Bangalore, Dorraya El‐Ashry, Cancer Biology & Therapy OncologyHematologyPharmacologyTherapeutic EfficacyProlonged Infusion Bryostatin-1	2002	29

Page 1